Announcements Trials
Browse Landscape

Status

Completed 4Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 78Observational 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Recurrence 3

Interventions

Surveys and Questionnaires 286Blood Specimen Collection 145Gene Expression Profiling 96Interviews as Topic 83Immunohistochemistry 78Polymerase Chain Reaction 64Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 58Microarray Analysis 55Flow Cytometry 53Radiotherapy 49Amplified Fragment Length Polymorphism Analysis 48Drug Therapy 46Observation 45Biopsy 42Reverse Transcriptase Polymerase Chain Reaction 39Bevacizumab 39Data Collection 35Sorafenib 29Psychiatric Rehabilitation 29Nivolumab 28palbociclib 26In Situ Hybridization, Fluorescence 26Rituximab 25Therapeutics 24Neoadjuvant Therapy 24Hepatectomy 24Docetaxel 24Colonoscopy 24Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Observational × pomalidomide × Clear all
NCT06163040 2025-07-31

A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Bristol-Myers Squibb

Completed
7 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03288974 2025-04-15

Pomalyst PMS

Celgene

Completed
397 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02555839 2025-03-28

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Celgene

Completed
127 enrolled
Plasma cell

Multiple Myeloma

NCT02164955 2022-10-20

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Celgene

Completed
775 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚔